Unveiling 26 Analyst Insights On Sarepta Therapeutics
Portfolio Pulse from Benzinga Insights
Sarepta Therapeutics (NASDAQ:SRPT) has received mixed analyst ratings over the past three months, with a majority being somewhat bullish. Analysts have set a 12-month average price target of $188.31, reflecting a 7.65% increase from the previous target. The company's financial health shows strong revenue growth and net margin, but challenges in ROE. Analysts' actions include maintaining, raising, and lowering ratings and price targets, indicating varied expectations for the company's future performance.
September 06, 2024 | 5:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sarepta Therapeutics has received a mix of analyst ratings, with a majority being somewhat bullish. The average 12-month price target is $188.31, up 7.65% from the previous target. The company's financials show strong revenue growth and net margin, but challenges in ROE.
The majority of analysts are somewhat bullish on SRPT, with a significant increase in the average price target. The company's strong revenue growth and net margin are positive indicators, although challenges in ROE may temper expectations. Overall, the sentiment and financial performance suggest a likely positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100